Scholars@Duke
Marcella Sarzotti-Kelsoe

Marcella Sarzotti-Kelsoe

Research Professor of Integrative Immunobiology
Integrative Immunobiology
marcella.kelsoe@duke.edu
DUMC Box 102800, Durham, NC 27710
2812 Erwin Rd., Suite 301, Durham, NC 27705

Selected Publications

Strengthening the Application of the DAIDS GCLP Guidelines: The Implementation of an Integrated Laboratory Oversight Framework.

Journal Article AIDS Res Hum Retroviruses · November 2024 The Division of AIDS (DAIDS) Good Clinical Laboratory Practice (GCLP) Guidelines establish a framework to guide the oversight of laboratories supporting DAIDS-sponsored clinical research or trials. Compliance with these guidelines promotes data reliability ... Full text Link to item Cite

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial.

Journal Article Science · January 7, 2022 In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as correlates of protection. These immune markers were measured at the time o ... Full text Link to item Cite

Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation.

Journal Article Sci Rep · December 14, 2021 Vaccine-induced neutralizing antibodies (nAbs) are key biomarkers considered to be associated with vaccine efficacy. In United States government-sponsored phase 3 efficacy trials of COVID-19 vaccines, nAbs are measured by two different validated pseudoviru ... Full text Link to item Cite

Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation.

Journal Article medRxiv · September 14, 2021 Vaccine-induced neutralizing antibodies (nAbs) are key biomarkers considered to be associated with vaccine efficacy. In United States Government-sponsored phase 3 efficacy trials of COVID-19 vaccines, nAbs are measured by two different validated pseudoviru ... Full text Link to item Cite

Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein.

Journal Article Clin Infect Dis · January 23, 2021 BACKGROUND: The Pox-Protein Public-Private Partnership is performing a suite of trials to evaluate the bivalent subtype C envelope protein (TV1.C and 1086.C glycoprotein 120) vaccine in the context of different adjuvants and priming agents for human immuno ... Full text Link to item Cite

Validation of a Triplex Pharmacokinetic Assay for Simultaneous Quantitation of HIV-1 Broadly Neutralizing Antibodies PGT121, PGDM1400, and VRC07-523-LS.

Journal Article Front Immunol · 2021 The outcome of the recent Antibody Mediated Prevention (AMP) trials that tested infusion of the broadly neutralizing antibody (bnAb) VRC01 provides proof of concept for blocking infection from sensitive HIV-1 strains. These results also open up the possibi ... Full text Link to item Cite

Optimization and qualification of a functional anti-drug antibody assay for HIV-1 bnAbs.

Journal Article J Immunol Methods · April 2020 The recent identification of human monoclonal antibodies with broad and potent neutralizing activity against HIV-1 (bnAbs) has resulted in substantial efforts to develop these molecules for clinical use in the prevention and treatment of HIV-1 infection. A ... Full text Link to item Cite

Implementation of a responsible conduct of research education program at Duke University School of Medicine.

Journal Article Account Res · July 2019 Academic medical centers rarely require all of their research faculty and staff to participate in educational programs on the responsible conduct of research (RCR). There is also little published evidence of RCR programs addressing high-profile, internal c ... Full text Link to item Cite

Qualified Biolayer Interferometry Avidity Measurements Distinguish the Heterogeneity of Antibody Interactions with Plasmodium falciparum Circumsporozoite Protein Antigens.

Journal Article J Immunol · August 15, 2018 Ab avidity is a measure of the overall strength of Ab-Ag interactions and hence is important for understanding the functional efficiency of Abs. In vaccine evaluations, Ab avidity measurements can provide insights into immune correlates of protection and g ... Full text Link to item Cite

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.

Journal Article Lancet HIV · July 2018 BACKGROUND: Modest efficacy was reported for the HIV vaccine tested in the RV144 trial, which comprised a canarypox vector (ALVAC) and envelope (env) glycoprotein (gp120). These vaccine components were adapted to express HIV-1 antigens from strains circula ... Full text Link to item Cite

Optimization and qualification of an Fc Array assay for assessments of antibodies against HIV-1/SIV.

Journal Article J Immunol Methods · April 2018 The Fc Array is a multiplexed assay that assesses the Fc domain characteristics of antigen-specific antibodies with the potential to evaluate up to 500 antigen specificities simultaneously. Antigen-specific antibodies are captured on antigen-conjugated bea ... Full text Link to item Cite

Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial.

Journal Article J Infect Dis · March 28, 2018 BACKGROUND: HVTN 505 was a human immunodeficiency virus type 1 (HIV-1) preventive vaccine efficacy trial of a DNA/recombinant adenovirus serotype 5 (rAd5) vaccine regimen. We assessed antibody responses measured 1 month after final vaccination (month 7) as ... Full text Link to item Cite

Validation of an automated system for aliquoting of HIV-1 Env-pseudotyped virus stocks.

Journal Article PLoS One · 2018 The standardized assessments of HIV-specific immune responses are of main interest in the preclinical and clinical stage of HIV-1 vaccine development. In this regard, HIV-1 Env-pseudotyped viruses play a central role for the evaluation of neutralizing anti ... Full text Link to item Cite

Profiling the neutralizing antibody response in chronically HIV-1 CRF07_BC-infected intravenous drug users naïve to antiretroviral therapy.

Journal Article Sci Rep · April 7, 2017 Characterizing neutralizing antibody (NAb) responses in individuals infected with diverse HIV-1 strains is necessary to reveal the novel targets for regional preventive and therapeutic strategies development. We evaluated the prevalence, breadth, and poten ... Full text Link to item Cite

Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission.

Journal Article J Clin Invest · July 1, 2015 Despite the wide availability of antiretroviral drugs, more than 250,000 infants are vertically infected with HIV-1 annually, emphasizing the need for additional interventions to eliminate pediatric HIV-1 infections. Here, we aimed to define humoral immune ... Full text Open Access Link to item Cite

Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1.

Journal Article J Immunol Methods · July 2014 The TZM-bl assay measures antibody-mediated neutralization of HIV-1 as a function of reductions in HIV-1 Tat-regulated firefly luciferase (Luc) reporter gene expression after a single round of infection with Env-pseudotyped viruses. This assay has become t ... Full text Link to item Cite

Optimization and validation of a neutralizing antibody assay for HIV-1 in A3R5 cells.

Journal Article J Immunol Methods · July 2014 A3R5 is a human CD4(+) lymphoblastoid cell line that was engineered to express CCR5 and is useful for the detection of weak neutralizing antibody responses against tier 2 strains of HIV-1. Here we describe the optimization and validation of the HIV-1 neutr ... Full text Open Access Link to item Cite

The External Quality Assurance Oversight Laboratory (EQAPOL) proficiency program for IFN-gamma enzyme-linked immunospot (IFN-γ ELISpot) assay.

Journal Article J Immunol Methods · July 2014 The interferon-gamma enzyme-linked immunospot (IFN-γ ELISpot) assay has been developed and used as an end-point assay in clinical trials for infectious diseases and cancer to detect the magnitude of antigen-specific immune responses. The ability to compare ... Full text Open Access Link to item Cite

The Center for HIV/AIDS Vaccine Immunology (CHAVI) multi-site quality assurance program for cryopreserved human peripheral blood mononuclear cells.

Journal Article J Immunol Methods · July 2014 The Center for HIV/AIDS Vaccine Immunology (CHAVI) consortium was established to determine the host and virus factors associated with HIV transmission, infection and containment of virus replication, with the goal of advancing the development of an HIV pro ... Full text Open Access Link to item Cite

Implementation of Good Clinical Laboratory Practice (GCLP) guidelines within the External Quality Assurance Program Oversight Laboratory (EQAPOL).

Journal Article J Immunol Methods · July 2014 The EQAPOL contract was awarded to Duke University to develop and manage global proficiency testing programs for flow cytometry-, ELISpot-, and Luminex bead-based assays (cytokine analytes), as well as create a genetically diverse panel of HIV-1 viral cult ... Full text Open Access Link to item Cite

Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies.

Journal Article J Virol · March 2014 UNLABELLED: Standardized assessments of HIV-1 vaccine-elicited neutralizing antibody responses are complicated by the genetic and antigenic variability of the viral envelope glycoproteins (Envs). To address these issues, suitable reference strains are need ... Full text Link to item Cite

Implementation of Good Clinical Laboratory Practice (GCLP) guidelines within the External Quality Assurance Program Oversight Laboratory (EQAPOL)

Journal Article Journal of Immunological Methods · January 1, 2014 The EQAPOL contract was awarded to Duke University to develop and manage global proficiency testing programs for flow cytometry-, ELISpot-, and Luminex bead-based assays (cytokine analytes), as well as create a genetically diverse panel of HIV-1 viral cult ... Full text Open Access Cite

Post-transplantation B cell function in different molecular types of SCID.

Journal Article J Clin Immunol · January 2013 PURPOSE: Severe combined immunodeficiency (SCID) is a syndrome of diverse genetic cause characterized by profound deficiencies of T, B and sometimes NK cell function. Non-ablative HLA-identical or rigorously T cell-depleted haploidentical parental bone mar ... Full text Open Access Link to item Cite

Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B'-infected former plasma donors from China naive to antiretroviral therapy.

Journal Article J Gen Virol · October 2012 Broadly neutralizing antibodies (NAbs) such as those generated in chronic human immunodeficiency virus type 1 (HIV-1) infection are considered a key component for an effective HIV-1 vaccine. Here, we measured NAb responses using a panel of 25 Env-pseudotyp ... Full text Link to item Cite

Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection.

Journal Article J Virol · April 2012 HIV-exposed, uninfected (EUN) babies born to HIV-infected mothers are examples of natural resistance to HIV infection. In this study, we evaluated the titer and neutralizing potential of gp41-specific maternal antibodies and their correlation with HIV tran ... Full text Link to item Cite

Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells.

Journal Article J Immunol Methods · January 31, 2012 Recent advances in assay technology have led to major improvements in how HIV-1 neutralizing antibodies are measured. A luciferase reporter gene assay performed in TZM-bl (JC53bl-13) cells has been optimized and validated. Because this assay has been adopt ... Full text Link to item Cite

An automated HIV-1 Env-pseudotyped virus production for global HIV vaccine trials.

Journal Article PLoS One · 2012 BACKGROUND: Infections with HIV still represent a major human health problem worldwide and a vaccine is the only long-term option to fight efficiently against this virus. Standardized assessments of HIV-specific immune responses in vaccine trials are essen ... Full text Link to item Cite

International technology transfer of a GCLP-compliant HIV-1 neutralizing antibody assay for human clinical trials.

Journal Article PLoS One · 2012 The Collaboration for AIDS Vaccine Discovery/Comprehensive Antibody-Vaccine Immune Monitoring Consortium (CAVD/CA-VIMC) assisted an international network of laboratories in transferring a validated assay used to judge HIV-1 vaccine immunogenicity in compli ... Full text Link to item Cite

Post-Transplantation B Cell Function in Different Molecular Types of SCID

Journal Article Journal of Clinical Immunology · 2012 Cite

The long and the short of telomeres in bone marrow recipient SCID patients.

Journal Article Immunol Res · April 2011 Telomeres are noncoding DNA regions at the end of the chromosomes that are crucial for genome stability. Since telomere length decreases with cell division, they can be used as a signature of cell proliferation history. T-cell reconstitution in severe comb ... Full text Link to item Cite

Thymic output, T-cell diversity, and T-cell function in long-term human SCID chimeras.

Journal Article Blood · August 13, 2009 Featured Publication Severe combined immunodeficiency (SCID) is a syndrome of diverse genetic cause characterized by profound deficiencies of T, B, and sometimes NK-cell function. Nonablative human leukocyte antigen-identical or rigorously T cell-depleted haploidentical parent ... Full text Link to item Cite

Evaluation and recommendations on good clinical laboratory practice guidelines for phase I-III clinical trials.

Journal Article PLoS Med · May 26, 2009 Featured Publication Marcella Sarzotti-Kelsoe and colleagues harmonize various approaches to Good Clinical Laboratory Practice for clinical trials into a single set of recommendations. ... Full text Open Access Link to item Cite

Endpoint Assays in HIV-1 Vaccine Trials: Functioning in a Good Laboratory Practices Environment

Chapter · April 8, 2008 An HIV-1 vaccine is the best public health tool for stemming the AIDS pandemic, now in its third decade. Studies from HIV-1 infected humans who control infection, animal model experiments, as well as historic experience with licensed vaccines suggest that ... Full text Cite

Review of 54 patients with complete DiGeorge anomaly enrolled in protocols for thymus transplantation: outcome of 44 consecutive transplants.

Journal Article Blood · May 15, 2007 Featured Publication The purpose of this study was to characterize a large group of infants with complete DiGeorge anomaly and to evaluate the ability of thymus transplantation to reconstitute immune function in these infants. DiGeorge anomaly is characterized by varying defec ... Full text Link to item Cite

T-B+NK+ severe combined immunodeficiency caused by complete deficiency of the CD3zeta subunit of the T-cell antigen receptor complex.

Journal Article Blood · April 15, 2007 Featured Publication CD3zeta is a subunit of the T-cell antigen receptor (TCR) complex required for its assembly and surface expression that also plays an important role in TCR-mediated signal transduction. We report here a patient with T(-)B(+)NK(+) severe combined immunodefi ... Full text Link to item Cite

Neonate-primed CD8+ memory cells rival adult-primed memory cells in antigen-driven expansion and anti-viral protection.

Journal Article Int Immunol · February 2006 Featured Publication Immunizations early in life, when the host is most susceptible to infection, allow protective immunological memory to develop. Decreasing the dose of Cas-Br-E murine leukemia virus when priming neonatal mice results in adult-like, Type 1 protective respons ... Full text Link to item Cite

SpA: web-accessible spectratype analysis: data management, statistical analysis and visualization.

Journal Article Bioinformatics · September 15, 2005 SUMMARY: SpA is a web-accessible system for the management, visualization and statistical analysis of T-cell receptor spectratype data. Users upload data from their spectratype analyzers to SpA, which saves the raw data and user-defined supplementary covar ... Full text Link to item Cite

Statistical analysis of antigen receptor spectratype data.

Journal Article Bioinformatics · August 15, 2005 MOTIVATION: The effectiveness of vertebrate adaptive immunity depends crucially on the establishment and maintenance of extreme diversity in the antigen receptor repertoire. Spectratype analysis is a method used in clinical and basic immunological settings ... Full text Link to item Cite

Postnatal thymus transplantation with immunosuppression as treatment for DiGeorge syndrome.

Journal Article Blood · October 15, 2004 Featured Publication Complete DiGeorge syndrome is a fatal congenital disorder characterized by athymia, hypoparathyroidism, and heart defects. Less than half of patients are 22q11 hemizygous. The goal of this study was to assess if immune suppression followed by postnatal thy ... Full text Link to item Cite

Glucose-regulated protein 94/glycoprotein 96 elicits bystander activation of CD4+ T cell Th1 cytokine production in vivo.

Journal Article J Immunol · April 1, 2004 Featured Publication Glucose-regulated protein 94 (GRP94/gp96), the endoplasmic reticulum heat shock protein 90 paralog, elicits both innate and adaptive immune responses. Regarding the former, GRP94/gp96 stimulates APC cytokine expression and dendritic cell maturation. The ad ... Full text Link to item Cite

Complete DiGeorge syndrome: development of rash, lymphadenopathy, and oligoclonal T cells in 5 cases.

Journal Article J Allergy Clin Immunol · April 2004 BACKGROUND: Five patients with DiGeorge syndrome presented with infections, skin rashes, and lymphadenopathy after the newborn period. T-cell counts and function varied greatly in each patient. Initial laboratory testing did not suggest athymia in these pa ... Full text Link to item Cite

Thymus transplantation in complete DiGeorge syndrome: immunologic and safety evaluations in 12 patients.

Journal Article Blood · August 1, 2003 Featured Publication Complete DiGeorge syndrome is a fatal condition in which infants have no detectable thymus function. The optimal treatment for the immune deficiency of complete DiGeorge syndrome has not been determined. Safety and efficacy of thymus transplantation were e ... Full text Link to item Cite

T cell repertoire development in humans with SCID after nonablative allogeneic marrow transplantation.

Journal Article J Immunol · March 1, 2003 Featured Publication Transplantation of HLA-identical or haploidentical T cell-depleted allogeneic bone marrow (BM) into SCID infants results in thymus-dependent T cell development in the recipients. Immunoscope analysis of the TCR V beta repertoire was performed on 15 SCID pa ... Full text Link to item Cite

GRP94 (gp96) and GRP94 N-terminal geldanamycin binding domain elicit tissue nonrestricted tumor suppression.

Journal Article J Exp Med · December 2, 2002 Featured Publication In chemical carcinogenesis models, GRP94 (gp96) elicits tumor-specific protective immunity. The tumor specificity of this response is thought to reflect immune responses to GRP94-bound peptide antigens, the cohort of which uniquely identifies the GRP94 tis ... Full text Link to item Cite

Enhanced type 1 immunity after secondary viral challenge in mice primed as neonates.

Journal Article J Immunol · September 15, 2002 Featured Publication The goal of infant immunization against viral infection is to develop protective long term memory responses. Priming neonatal mice with a low dose of Cas-Br-E murine leukemia virus (Cas) results in adult-like, type 1 protective responses. However, other st ... Full text Link to item Cite

CD4+Thy1- thymocytes with a Th-type 2 cytokine response.

Journal Article Int Immunol · January 2001 Featured Publication We have identified a small subset of CD3(+), CD4(+), CD8(-) thymocytes that do not express Thy1 (CD90). This Thy1(-) subset represents 1-3.7% of the total number of thymocytes in a naive mouse. CD4(+)Thy1(-) thymocytes express high levels of CD3, intermedi ... Full text Link to item Cite

gammadelta T cells are a component of early immunity against preerythrocytic malaria parasites.

Journal Article Infect Immun · April 2000 We tested the hypothesis that gammadelta T cells are a component of an early immune response directed against preerythrocytic malaria parasites that are required for the induction of an effector alphabeta T-cell immune response generated by irradiated-spor ... Full text Link to item Cite

T cell immunity in neonates.

Journal Article Immunol Res · 2000 Typically, neonates exhibit decreased or aberrant cellular immune responses when compared to adults, resulting in increased susceptibility to infection. However, it is clear that newborns are able to generate adult-like protective T cell responses under ce ... Full text Link to item Cite

Cellular immune responses in neonates.

Journal Article Int Rev Immunol · 2000 Featured Publication Reduced numbers of lymphocytes and antigen presenting cells have been described as some of the main factors responsible for antigenic tolerance or low responsiveness in neonates. However, by changing the parameters of immunization, such as dose of antigen ... Full text Link to item Cite

DNA immunization of infants: potential and limitations.

Journal Article Vaccine · 1998 DNA immunization is a relatively new and efficacious approach to vaccination. Only recently have we begun to test the efficacy of DNA vaccines in infants. DNA vaccines for a retrovirus, hepatitis B, influenza, rabies, measles, tetanus toxoid, and sendai vi ... Full text Link to item Cite

Induction of cytotoxic T cell responses in newborn mice by DNA immunization.

Journal Article Vaccine · June 1997 Featured Publication Cytotoxic T cells (CTL) play a critical role in controlling viral infections. Infection of neonatal NFSIN mice with a high dose of Cas-Br-M murine leukemia virus, a neuropathogenic type C retrovirus, results in virus-induced neurologic disease and in their ... Full text Link to item Cite

Immunologic tolerance.

Journal Article Curr Opin Hematol · January 1997 Featured Publication Understanding the phenomenon of immunologic tolerance and the mechanisms that control it at different stages of lymphocyte development is rapidly progressing. This review summarizes some recent findings in T-cell tolerance, focusing on neonatal and periphe ... Full text Link to item Cite

Response: immunological tolerance.

Journal Article Science · June 7, 1996 Full text Link to item Cite

Immunological tolerance.

Journal Article Science · June 7, 1996 Full text Link to item Cite

Induction of protective CTL responses in newborn mice by a murine retrovirus.

Journal Article Science · March 22, 1996 Featured Publication The susceptibility of neonates to virus-induced disease is thought to reflect, in part, the immaturity of their immune systems. However, inoculation of newborn mice with low doses of Cas-Br-M murine leukemia virus induced a protective cytotoxic T lymphocyt ... Full text Link to item Cite

Retrovirus-elicited interleukin-12 and tumour necrosis factor-alpha as inducers of interferon-gamma-mediated pathology in mouse AIDS.

Journal Article Immunology · March 1996 Spleen cells from mice resistant or sensitive to mouse acquired immune deficiency syndrome (MAIDS) were examined for cytokine mRNA. In MAIDS-resistant BALB/c mice, cytokine transcripts peaked at 1 week after infection with Type 1 cytokines [interleukin-2 ( ... Full text Link to item Cite

Immunogenic determinants of a neuropathogenic murine leukemia virus.

Journal Article J Virol · November 1995 Previous studies of Cas-Br-M murine leukemia virus (MuLV) (Cas-MuLV) infection demonstrated that cytotoxic T cells (CTL) of the CD8+ phenotype play a role in resistance to the neuropathogenic effects of the virus in NFS/N mice. In the current study, we sou ... Full text Link to item Cite

Treatment of intracranial alphavirus infections in mice by a combination of specific antibodies and an interferon inducer.

Journal Article Am J Trop Med Hyg · January 1995 Finding an effective treatment for viral infections that cause encephalitis remains an important problem. A model of human alphavirus infections, Semliki Forest virus, causes lethal encephalitis in weanling mice. Mice are viremic within 24 hr of an intrape ... Full text Link to item Cite

Ultraviolet-light-inactivated Cas-Br-M murine leukemia virus induces a protective CD8+ cytotoxic T lymphocyte response in newborn mice.

Journal Article AIDS Res Hum Retroviruses · December 1994 Newborn NFS/N mice are susceptible to the neurological disease induced by infection with Cas-Br-M murine leukemia virus (Cas), and do not develop a protective cytotoxic T cell (CTL)-mediated response to Cas infection. Here we demonstrate that whole UV ligh ... Full text Link to item Cite

IFN-gamma production in response to neuropathogenic Cas-Br-M murine leukemia virus infection.

Journal Article Viral Immunol · 1993 T cell-mediated production of IFN-gamma followed infection of adult, but not neonatal NFS/N mice with Cas-Br-M murine leukemia virus (Cas). The IFN-gamma response was associated with the appearance of CTL specific for Cas and with age-dependent resistance ... Full text Link to item Cite

Cloning of murine splenic T lymphocytes and natural killer (NK) cells on filter paper discs: detection of a novel NK/T phenotype.

Journal Article Eur J Immunol · March 1991 Discrete colonies of splenocytes were grown on filter paper discs in the presence of concanavalin A and interleukin 2. Phenotypic analysis of the colonies indicated that the majority expressed the Thy-1.2 marker and 72% of these co-expressed the CD3 molecu ... Full text Link to item Cite

Postinfection therapy of arbovirus infections in mice.

Journal Article Antimicrob Agents Chemother · December 1989 Most antiviral agents are efficacious prophylactically in vivo, and a few are efficacious for postinfection (p.i.) therapy. To explore possibilities for p.i. therapy of encephalogenic Banzi virus (BZV) and Semliki Forest virus infections in mice, we evalua ... Full text Link to item Cite

The in vivo antiviral effect of CL246,738 is mediated by the independent induction of interferon-alpha and interferon-beta.

Journal Article J Interferon Res · June 1989 An interferon (IFN) inducer and immunomodulator, CL246,738 [3,6-bis(2-piperidinoethoxy)acridine trihydrochloride], protected mice from lethal infection with Semliki Forest (SFV) and Banzi (BZV) viruses. A single oral dose of CL246,738 (5-150 mg/kg) adminis ... Full text Link to item Cite

Long-term killing of natural killer-resistant target cells by interferon-alpha-, interferon-gamma-, and interleukin-2-activated natural killer cells.

Journal Article Nat Immun Cell Growth Regul · 1989 The sensitivity of target cells to natural killer (NK) cell-mediated cytotoxicity was investigated. Five target cell lines were examined for susceptibility to killing by activated NK cells in a 4-hour cytotoxicity assay: one of them (K562) was highly sensi ... Link to item Cite

Protection of mice from Semliki Forest virus infection by lymphocytes treated with low levels of interferon.

Journal Article Mol Biother · 1989 These studies provide the first evidence that adoptive transfer of syngeneic mouse (BALB/c) lymphocytes treated with low levels of mouse interferon (IFN)-alpha/beta can result in sufficient protection to protect mice from Semliki Forest virus (SFV) infecti ... Link to item Cite

EL-4 metastases in spleen and bone marrow suppress the NK activity generated in these organs.

Journal Article Int J Cancer · January 15, 1987 The relationship between metastatic cells in the spleen and bone marrow of tumor-bearing mice and the NK activity generated in vitro by cells obtained from these organs was investigated. EL-4 lymphoma and B16 melanoma cells injected intraperitoneally into ... Full text Link to item Cite

Interferon-mediated protection of B16 melanoma cells from cytotoxicity by activated macrophages.

Journal Article Cell Immunol · June 1986 Corynebacterium parvum-activated macrophages (M phi), purified by adherence, were cytotoxic for B16 melanoma cells maintained in vitro. Pretreatment of the melanoma cells for 18 hr with interferon-alpha/beta or -gamma (IFN-alpha/beta or -gamma) caused a re ... Full text Link to item Cite

Characterization of cytotoxic cells generated from in vitro cultures of murine bone marrow cells.

Journal Article Cell Immunol · April 15, 1985 Bone marrow cells cultured for 5-6 days generate cytotoxic activity against a number of natural killer (NK)-susceptible tumor cells. In this study, these bone marrow cytotoxic cells were compared to cells with NK activity obtained either from spleen cells ... Full text Link to item Cite

EL-4 metastases to lymphoid organs correlate with lack of local NK activity

Journal Article Federation Proceedings · January 1, 1985 Cite

Immune (gamma) interferon production by a murine T cell lymphoma: requirements for macromolecular synthesis and lack of relationship with cell cycle.

Journal Article Infect Immun · August 1983 Macromolecular synthesis of immune interferon (IFN-gamma) by the L12-R4 T cell lymphoma, stimulated by phorbol myristic acetate, was studied by using reversible inhibitors of protein synthesis, puromycin and cycloheximide, and an irreversible inhibitor of ... Full text Link to item Cite

Rous sarcoma virus-induced tumours in mice. II. Contribution of H-2 and non-H-2 alloantigen barriers to tumour immunogenicity in vivo.

Journal Article J Immunogenet · June 1983 The features of the immune recognition of a murine fibrosarcoma induced by Rous sarcoma virus were tested in histocompatible and histoincompatible mice. No evidence of a genetic regulation of spontaneous reactivity to tumour-associated antigens was found i ... Full text Link to item Cite

Some characteristics of mouse immune (y) interferon produced by a T-lymphoma cell line.

Journal Article Microbiologica · April 1983 Mouse immune interferon was produced from a T-lymphoma cell line, L12-R4, upon stimulation with phorbol myristic acetate at a concentration of 2 x 10(-7) M/ml. The crude interferon, concentrated by precipitation with (NH4)2SO4 at concentration of 80%, was ... Link to item Cite

Interferon production in mixed cultures of murine leukocytes and syngeneic L1210 leukemia cells.

Journal Article Boll Ist Sieroter Milan · 1982 Spleen cells from DBA/2 mice did not proliferate, but released interferon (IFN) when cultured in the presence of mitomycin C-treated syngeneic L1210 leukemia cells apparently free from mycoplasma and common non-oncogenic viral infections. IFN titers reache ... Link to item Cite

[Characteristics of cells producing immune interferon].

Journal Article G Batteriol Virol Immunol · 1981 Link to item Cite